ライフサイエンスコーパス: renal impairment

1 study arm (all cases and among those without renal impairment).

2 athic changes, low platelet count, and acute renal impairment).

3 gulation therapy, and substantial hepatic or renal impairment.

4 n was increased in atherosclerotic mice with renal impairment.

5 in HIV-positive persons without preexisting renal impairment.

6 s trended lower at baseline and 3 hours with renal impairment.

7 elderly people with no clinical diagnosis of renal impairment.

8 recommended affect acute rejection rates and renal impairment.

9 e renal impairment compared to those with no renal impairment.

10 mpared with the AF population without severe renal impairment.

11 proportionally suppressed with the degree of renal impairment.

12 s seen in the patient population with severe renal impairment.

13 e deliberately excluded patients with severe renal impairment.

14 sity anticoagulation in patients with severe renal impairment.

15 ion between invasive Moraxella infection and renal impairment.

16 cal appearance, proteinuria, and progressive renal impairment.

17 a high dose, and subgroups of patients with renal impairment.

18 yocardial injury, myocardial infarction, and renal impairment.

19 thic hemolytic anemia, thrombocytopenia, and renal impairment.

20 midronate dose in patients with pre-existing renal impairment.

21 Of 4726 patients identified, 904 (19%) had renal impairment.

22 buminuria and 1,449 (29%) of 5,032 developed renal impairment.

23 veloped albuminuria and nearly 30% developed renal impairment.

24 eloped albuminuria and 1,132 (28%) developed renal impairment.

25 herosclerosis, even in the setting of subtle renal impairment.

26 racial disparities at the highest levels of renal impairment.

27 d event, infection, diabetes, malignancy, or renal impairment.

28 or patients with heart failure, diabetes, or renal impairment.

29 after liver transplantation, but they cause renal impairment.

30 should be used with caution in patients with renal impairment.

31 ut ethnic/racial disparities for early-onset renal impairment.

32 effect of TAVR among patients with baseline renal impairment.

33 in which both groups had a similar level of renal impairment.

34 21 of whom had HIVN with varying degrees of renal impairment.

35 led five loci involved in the development of renal impairment.

36 scintigraphic parameters and the severity of renal impairment.

37 ole of the tubulointerstitium in the role of renal impairment.

38 n, and had a lower hematocrit value and more renal impairment.

39 red in patients with moderate, but not mild, renal impairment.

40 f of the genetic variation in key indices of renal impairment.

41 er aortic valve replacement in patients with renal impairment.

42 an who presented with nephrotic syndrome and renal impairment.

43 , hypertension, hyperlipidemia, smoking, and renal impairment.

44 patients with atrial fibrillation (AF) with renal impairment.

45 clinical indications or severity of baseline renal impairment.

46 d introduction of sirolimus in patients with renal impairment.

47 mg every 48 hours in patients with moderate renal impairment.

48 t at the detriment of patients with ESLD and renal impairment.

49 oronary syndrome (NSTE-ACS) in patients with renal impairment.

50 ulation of patients with type 2 diabetes and renal impairment.

51 cular disease, inflammation, thrombosis, and renal impairment.

52 nts with AF are validated but do not include renal impairment.

53 proliferation were significantly enhanced in renal impairment.

54 vascular inflammation and atherosclerosis in renal impairment.

55 e (22.1%), significant bleeding (13.9%), and renal impairment (11.9%) were the most common.

56 ort including patients with risk factors for renal impairment a marked decline in renal function was

57 ere presence of CRAB (C=calcium elevation; R=renal impairment; A=anaemia; B=bone involvement) criteri

58 icant, independent predictors for death were renal impairment, acidosis, parasitemia, and plasma PfHR

59 independent predictors of AKI were baseline renal impairment (adjusted hazard ratio, 4.15; 95% confi

60 infection was independently associated with renal impairment (adjusted odds ratio [aOR] = 2.1; 95% c

61 Subclinical renal impairment affects approximately 50% of scleroderm

62 NSF develops in patients with renal impairment after exposure to gadopentetate dimeglu

63 account for worse outcomes in patients with renal impairment after MI.

64 ribute to the increased risk associated with renal impairment after myocardial infarction (MI).

65 infection was independently associated with renal impairment, albuminuria, and proximal renal tubula

66 In bivariate analyses, the odds of renal impairment among black women was estimated to be 2

67 The frequency of baseline renal impairment among high-risk and inoperable patients

68 nt for the association between ethnicity and renal impairment among men.

69 ow-up > or =1 year, 38% of patients with any renal impairment and 51% with moderate to severe impairm

70 ng the pathophysiologic interactions between renal impairment and brain function is important in orde

71 While the association between renal impairment and cardiovascular disease (CVD) is wel

72 Irrespective of diagnosis, patients with renal impairment and elevated cardiac troponin concentra

73 ffected by HFD, in marked contrast to severe renal impairment and glomerulopathy in the wild-type mic

74 d 0.78 million women with moderate or severe renal impairment and gout.

75 Renal impairment and high model of end-stage liver disea

76 -3 concentrations increased with progressive renal impairment and independently associated with cardi

77 has not been studied in patients with severe renal impairment and is not recommended in this setting.

78 ke (IS)/thromboembolism (TE) associated with renal impairment and its incremental predictive value ov

79 atients with white-coat hypertension develop renal impairment and left ventricular hypertrophy.

80 udies characterizing the association between renal impairment and mortality in 80,098 hospitalized an

81 to a PK/PD-driven dosing approach, baseline renal impairment and older age strongly predict AKI occu

82 ion with respect to comorbidities, including renal impairment and overall prognosis.

83 EBR/GZR is approved for use in patients with renal impairment and patients on dialysis, but not in th

84 atients are not safe in patients with severe renal impairment and patients on dialysis.

85 pressants given as monotherapy, for example, renal impairment and posttransplant lymphoproliferative

86 This deletion attenuated renal impairment and reduced tubular apoptosis in mercur

87 the post-treatment development of persistent renal impairment and the 60-day rate of death or readmis

88 kinetics of imatinib in cancer patients with renal impairment and to develop dosing guidelines for im

89 erated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for ox

90 ation between race/ethnicity and early-onset renal impairment and to identify other risk factors that

91 d perfusion is contraindicated (eg, allergy, renal impairment) and holds promise in differentiating t

92 bidities (notably cardiovascular disease and renal impairment) and the need to avoid hypoglycaemia, w

93 A total of 63% of patients had any renal impairment, and 29% had moderate to severe impairm

94 t of necrotizing crescentic GN, albuminuria, renal impairment, and accumulation of CD4(+) T cells and

95 were independently associated with ascites, renal impairment, and bacterial infection.

96 Acidosis, cerebral involvement, renal impairment, and chronic illness are key independen

97 ables such as systemic ventricular function, renal impairment, and diuretic therapy (adjusted hazard

98 recipients without causing severe acidosis, renal impairment, and hemodynamic instability.

99 sulodexide in patients with type 2 diabetes, renal impairment, and macroalbuminuria.

100 adjustment is not required in patients with renal impairment, and monitoring can be less intense bec

101 HD had more heart failure, coronary disease, renal impairment, and persistent atrial fibrillation.

102 known about the effects of milder degrees of renal impairment, and previous studies have relied on le

103 sulodexide in patients with type 2 diabetes, renal impairment, and significant proteinuria (>900 mg/d

104 od from SSc-related gastroesophageal reflux, renal impairment, and skin fibrosis.

105 be challenging to interpret in patients with renal impairment, and the effectiveness of testing in th

106 % confidence interval [CI]: 0.75 to 1.49 for renal impairment; and hazard ratio: 1.09; 95% CI: 0.84 t

107 Cardiovascular disease and renal impairment are common in cirrhotic transplant cand

108 onset of dementia in patients with moderate renal impairment are needed.

109 n race/ethnicity related risk of early-onset renal impairment are particularly large among men and ar

110 odystrophy, from developing in patients with renal impairment are reviewed.

111 Renal impairment as assessed by serum creatinine was mor

112 diac troponin identified fewer patients with renal impairment as low risk and more as high risk, but

113 presentation identified 17% of patients with renal impairment as low risk for the primary outcome (ne

114 re the role of toxic solutes retained due to renal impairment as mediators of cardiovascular risk.

115 ir impact on UPV and the other parameters of renal impairment, as well as an interaction with BP.

116 er transplantation were associated with less renal impairment at 1 year (RR = 0.51 [0.38-0.69]), with

117 the 99th centile were lower in patients with renal impairment at 50.0% (95% CI, 45.2%-54.8%) and 70.9

118 for age >50 years (HR 3.49, P = 0.087), mild renal impairment at baseline (HR 4.49, P = 0.073), and h

119 choosing telavancin in patients with severe renal impairment at baseline.

120 ty rates in patients with moderate to severe renal impairment at baseline; however, on subsequent ana

121 rity of histopathologic lesions, severity of renal impairment at diagnosis, and hypertension.

122 Fifty-two (2.7%) women and 39 (2.4%) men had renal impairment at the year 15 examination.

123 Familial childhood gout with progressive renal impairment attributable to mutations of the uromod

124 nephrectomized normal littermates to exhibit renal impairment because of the combination of reduced n

125 ence of hypertension, diabetes mellitus, and renal impairment (but had higher prevalence of stroke an

126 Rf-1 strongly affects the risk of renal impairment, but has no significant effect on blood

127 al agents (ARVs) are associated with chronic renal impairment, but the extent of such adverse events

128 disoproxil fumarate (TDF) has been linked to renal impairment, but the extent to which this impairmen

129 rsus 5% [95% CI: 7.3% to 38%]; P=0.006), and renal impairment by 23% (30% versus 7%; [95% CI: 6.4 to

130 Renal impairment by both creatinine and eGFR definitions

131 Here, we describe a 40-year-old man with renal impairment, cardiac and GI symptoms, and periphera

132 ia (microalbuminuria or macroalbuminuria) or renal impairment (Cockcroft-Gault estimated creatinine c

133 , 22.0) respectively among those with severe renal impairment compared to those with no renal impairm

134 Events were more common in patients with renal impairment compared with those without (48% versus

135 hepatorenal syndrome (HRS2) is a functional renal impairment complicating end-stage liver disease.

136 Renal impairment confers an increased risk of stroke, bl

137 ll-cause mortality risks associated with any renal impairment (creatinine >1.0 mg/dl, creatinine clea

138 3 patients with type 2 diabetes mellitus and renal impairment (creatinine 1.5-3 mg/dL) who were candi

139 Subjects with preexisting renal impairment (creatinine clearance, 40-60 mL/minute)

140 The study population was stratified by renal impairment defined by serum creatinine level and b

141 ease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both.

142 Persistent renal impairment developed in 15.0% of patients in the r

143 r disease, hypertension, raised cholesterol, renal impairment, diabetes, obesity, hypothyroidism, hyp

144 After adjustment for CHADS(2) risk factors, renal impairment did not significantly increase the risk

145 age, a preexisting do-not-resuscitate order, renal impairment, disseminated cancer, preoperative seps

146 cardiac troponin I in those with and without renal impairment (estimated glomerular filtration rate <

147 We compared prevalence of renal impairment (estimated glomerular filtration rate [

148 This substudy of patients with baseline renal impairment (estimated glomerular filtration rate [

149 s zanamivir 600 mg twice daily, adjusted for renal impairment, for up to 10 days.

150 Increasing heart rate and chronic renal impairment further predicted mortality.

151 ry amyloidosis that typically manifests with renal impairment, gastrointestinal (GI) symptoms, and si

152 Fifty-one patients (CNI group) with renal impairment (GFR < or =50 mL/min) maintained on CNI

153 group) of whom 58 (group A) had CNI-induced renal impairment (glomerular filtration rate [GFR] <50 m

154 Renal impairment has not been reported as a safety signa

155 BG) surgery, the impact of lesser degrees of renal impairment has not been well studied.

156 Renal impairment (hazard ratio, 2.07; 95% confidence int

157 -generated random sequence and stratified by renal impairment, HbA1c, and background antidiabetes med

158 sed age (HR 1.63), U.S. residency (HR 1.61), renal impairment (HR 1.50), stroke/transient ischemic at

159 sex (HR, 1.70; 95% CI, 1.03-2.80; P=0.036), renal impairment (HR, 2.12; 95% CI, 1.20-3.73; P=0.010),

160 , GI disease (HR, 7.3; 95% CI, 3.6 to 14.8), renal impairment (HR, 8.3; 95% CI, 3.0 to 23.2), neurolo

161 nce interval [CI]: 1.59 to 2.77; p < 0.001); renal impairment (HR: 1.98; 95% CI: 1.42 to 2.76; p < 0.

162 erious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enala

163 d odds ratios associated with severe to mild renal impairment, ie.

164 We estimated the prevalence of renal impairment in heart failure (HF) patients and the

165 ase, it is unclear whether the prognosis for renal impairment in HF patients differs by race.

166 Renal impairment in HF patients is associated with exces

167 r use were independent predictors of chronic renal impairment in HIV-positive persons without preexis

168 ch is significantly related to the degree of renal impairment in patients.

169 established and novel biologic mechanisms of renal impairment in renal diseases.

170 The mechanisms and significance of chronic renal impairment in scleroderma need to be better define

171 ys is a marker for progression of CKD in the Renal Impairment in Secondary Care (RIISC) cohort, a pro

172 ascular events/procedures and development of renal impairment in the CAFE cohort (unadjusted, P<0.000

173 considered in the differential diagnosis of renal impairment in these patients.

174 xtramedullary involvement, and patients with renal impairment, including patients with renal failure

175 mpared with normal renal function, even mild renal impairment increased the 10-yr risk for mortality

176 Renal impairment increases the risk of stroke and bleedi

177 , pain, urinary tract obstruction with acute renal impairment, infection, procedure-related illness,

178 Pretransplant renal impairment is a predictor of cardiac event after l

179 Chronic renal impairment is an emerging problem in the managemen

180 Renal impairment is an emerging prognostic indicator in

181 ents with and without renal dysfunction, yet renal impairment is an important determinant of the prov

182 Although renal impairment is associated with accelerated cerebrov

183 Renal impairment is associated with adverse cardiovascul

184 Renal impairment is associated with an increased risk of

185 this study was to determine whether moderate renal impairment is associated with incident dementia am

186 Renal impairment is common among HF patients and confers

187 Renal impairment is highly prevalent among patients with

188 w atherosclerotic inflammation is altered in renal impairment is incompletely understood.

189 isks, but the influence of milder degrees of renal impairment is less well defined.

190 0 mg every 48 hours for adults with moderate renal impairment is often confusing and inconvenient.

191 min B-12 deficiency in a population in which renal impairment is prevalent.

192 isease (CKD), contrast media compatible with renal impairment is sorely needed.

193 dities, such as impaired glucose metabolism, renal impairment, left ventricular hypertrophy, heart fa

194 e often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL328

195 although it suggests that patients with less renal impairment might benefit.

196 Severe renal impairment more than doubled the risk for mortalit

197 Renal impairment (n=454 vs 317), hypotension (203 vs 145

198 acute rejection [n = 957] and two trials for renal impairment [n = 712]) showed that "reduced tacroli

199 Patients with renal impairment, obesity, or those who are critically i

200 consecutive liver transplant candidates with renal impairment of unclear etiology referred to determi

201 17a(-/-) bone marrow abolished the effect of renal impairment on aortic CD11b(+) myeloid cell accumul

202 the outcome in patients who received MMF for renal impairment on tacrolimus-based immunosuppression.

203 acute decompensated heart failure (ADHF) and renal impairment or diuretic resistance.

204 ated pulmonary capillary wedge pressure, and renal impairment or substantial diuretic requirement des

205 ent options for post-LT patients with severe renal impairment or who are on dialysis, nor do publishe

206 mic outcomes (myocardial infarction, stroke, renal impairment, or failure) were prespecified as copri

207 ction, recurrence of autoimmune process(es), renal impairment, or the concomitant presence of other m

208 The incremental predictive value of renal impairment over CHADS(2) and CHA(2)DS(2)-VASc were

209 97.5%-99.9%), in comparison with 56% without renal impairment (P<0.001) with similar performance (neg

210 ores did not influence likelihood of PTx and renal impairment predicted against PTx (OR 0.35, P < 0.0

211 A pretransplant score comprising renal impairment, prolonged QTc interval, and age older

212 patients with type 2 diabetes without overt renal impairment, raised ACR is associated with higher A

213 Moderate renal impairment, reflected by a higher SCr, is associat

214 essed in the kidney, further improves cardio-renal impairment remains unknown.

215 Among 65 patients treated for renal impairment, renal function improved in 20 (30.8%),

216 The rates of hyperkalemia, hypotension, and renal impairment/renal failure were higher in the aliski

217 cy and safety of MMF in patients with severe renal impairment requires further investigation.

218 s and management of multiple myeloma-related renal impairment (RI).

219 athogenesis of multiple myeloma (MM) related renal impairment (RI).

220 patients with type 2 diabetes without overt renal impairment (serum creatinine <150 micromol/L).

221 Neurological and renal impairments (serum creatinine, 0.87+/-0.20; median

222 isk factors for osteonecrosis of the jaw and renal impairment should be assessed, and any pending den

223 alvage in patients with significant baseline renal impairment that were previously denied interventio

224 5 mg twice daily appeared not to have severe renal impairment, the intended population for this dose.

225 hypotension, leukopenia, metabolic acidosis, renal impairment, thrombocytopenia, and disseminated coa

226 ents with deep vein thrombosis, hepatitis C, renal impairment, thyroid disease, and liver disease fro

227 Conclusion In patients with renal impairment undergoing transcatheter aortic valve r

228 When renal impairment was added to existing risk scoring syst

229 Renal impairment was associated with smaller LV and larg

230 Renal impairment was defined as creatinine > or =1.5 mg/

231 nverse of serum creatinine (1/SCr); moderate renal impairment was defined as SCr > or = 1.3 mg/dl for

232 an modify atherosclerosis in a model of mild renal impairment was examined.

233 In Cox regression analysis, pretransplant renal impairment was found to be an independent predicto

234 Baseline renal impairment was frequent among patients who underwe

235 Development of albuminuria or renal impairment was independently associated with incre

236 Renal impairment was not an independent predictor of IS/

237 s with telaprevir (TLV) and boceprevir (BOC) renal impairment was not reported as a relevant adverse

238 Renal impairment was present in 24% (48/202).

239 ess than 85 mm Hg (diastolic) if diabetes or renal impairment was present.

240 hymal stromal cells, postischemic functional renal impairment was reduced, but there was no evidence

241 hite women, and among black men, the odds of renal impairment were 9.0-fold that of white men.

242 ng guidelines for patients with pre-existing renal impairment were added to the zoledronic acid packa

243 th troponin concentrations >99th centile and renal impairment were at greater risk of subsequent myoc

244 Patients with severe renal impairment were excluded from the non-VKA oral ant

245 Additional independent risk factors for renal impairment were female sex, decreased waist circum

246 OR: 0.18, 95% CI: 0.04 to 0.75; P=0.006) and renal impairment were independent of other covariables.

247 ailure Assessment (SOFA), score and baseline renal impairment were significantly associated with AKI.

248 d physician diagnosis of gout and degrees of renal impairment were the primary focus of the present a

249 utcomes at 1 year, and even mild or moderate renal impairments were associated with an increased risk

250 cretion and plasma NOx levels (corrected for renal impairment) were inversely related to disease seve

251 Independent risk factors of IS/TE (including renal impairment) were investigated in Cox regression mo

252 kalemia (K+>7.0 meq/L) and a mild reversible renal impairment, which were thought to reflect in part

253 A pathophysiology that links renal impairment with cardiovascular risk has long been

254 els were used to estimate the association of renal impairment with incident dementia.

255 e first month was positively correlated with renal impairment within 1 year (r = 0.73; p = 0.003), bu

256 macokinetic data showed dose adjustments for renal impairment yielded similar zanamivir exposures.